Infectious Diarrhea: An Overview

被引:25
作者
Dickinson B. [1 ]
Surawicz C.M. [2 ]
机构
[1] Department of Medicine, University of Washington School of Medicine, Seattle
[2] Division of Gastroenterology, Department of Medicine, University of Washington School of Medicine, 325 9th Ave, Box 359773, Seattle, 98104, WA
关键词
Clostridium difficile infection (CDI); Fecal microbiota transplant (FMT); Infectious diarrhea; Oral rehydration solution (ORS); Post-infectious irritable bowel syndrome (PI-IBS); Probiotics; Recurrent Clostridium difficile infection (RCDI); Zinc;
D O I
10.1007/s11894-014-0399-8
中图分类号
学科分类号
摘要
Diarrheal disease, which is most often caused by infectious pathogens, is a significant cause of morbidity and mortality worldwide, especially in children. This is particularly true in developing countries. Recent outbreaks of infectious diarrhea in developed countries, including the USA, are often attributed to food handling and distribution practices and highlight the need for continued vigilance in this area. Another common cause of infectious diarrhea, Clostridium difficile infection (CDI), has historically been associated with the use of antibiotics and exposure to a health-care setting but is now increasingly common in the community in persons who lack the typical risk factors. Recent scientific advances have also led to new and proposed new therapies for infectious diarrhea, including fecal microbiota transplant (FMT) for recurrent C. difficile infection (RCDI), probiotics for prevention of antibiotic-associated diarrhea (AAD) and CDI, and the use of zinc supplementation in the treatment of acute diarrhea in children. Other therapies that have been in use for decades, such as the oral rehydration solution (ORS), continue to be the targets of scientific advancement in an effort to improve delivery and efficacy. Finally, post-infectious irritable bowel syndrome (PI-IBS) is an increasingly recognized occurrence. Attempts to understand the mechanism behind this phenomenon are underway and may provide insight into potential treatment options. © 2014, Springer Science+Business Media New York.
引用
收藏
页数:6
相关论文
共 67 条
  • [1] Centers for Disease Control and Prevention (CDC), Incidence and trends of infection with pathogens transmitted commonly through food—foodborne diseases active surveillance network, 10 U.S. sites, 1996–2012, MMWR Morb Mortal Wkly Rep, 62, 15, pp. 283-287, (2013)
  • [2] Gould L.H., Demma L., Jones T.F., Et al., Hemolytic uremic syndrome and death in persons with Escherichia coli 0157:H7 infection, foodborne disease active surveillance network sites, 2000–2006, Clin Infect Dis, 49, pp. 1480-1485, (2009)
  • [3] Frank C., Werber D., Cramer J.P., Et al., Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany, N Eng J Med, 365, 19, pp. 1771-1780, (2011)
  • [4] Mellmann A., Harmsen D., Cummings C.A., Et al., Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology, PLoS ONE, 6, (2011)
  • [5] Rhode H., Qin J., Cui Y., Et al., Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4, N Eng J Med, 365, pp. 718-724, (2011)
  • [6] Barton Behravesh C., Jones T.F., Vugia D.J., Et al., Deaths associated with bacterial pathogens transmitted commonly through food: foodborne disease active surveillance network (FoodNet), 1996–2005, J Infect Dis, 204, pp. 263-267, (2011)
  • [7] McCollum J.T., Cronquist A.B., Silk B.J., Et al., Multistate outbreak of listeriosis associated with cantaloupe, N Eng J Med, 369, 10, pp. 944-953, (2013)
  • [8] Arvelo W., Hinkle C.J., Nguyen T.A., Et al., Transmission risk factors and treatment of pediatric shigellosis during a large daycare center-associated outbreak of multidrug resistant Shigella sonnei: implications for the management of shigellosis outbreaks among children, Pediatr Infect Dis J, 28, pp. 976-980, (2009)
  • [9] CDC, Notes from the field: outbreak of infections caused by Shigella sonnei with decreased susceptibility to azithromycin—Los Angeles, California, 2012, MMWR Morb Mortal Wkly Rep, 62, 9, (2013)
  • [10] McFarland L.V., Emerging therapies for Clostridium difficile infections, Exp Opin Emerg Drugs, 16, pp. 425-439, (2011)